As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Our Latest News
Presenting our ESG Report
Sanofi’s ESG Integrated Report 2022 describes the progress we have made against our business-integrated CSR strategy.
Our First ESG Investor Day
In July 2022, Sanofi held its first ESG Investor Day live in its Paris HQ.
Our Double Materiality Assessment
Sanofi recently completed its first double materiality assessment to gain insights into Sanofi’s impact on the external environment and its ESG risks and opportunities and to prepare for the upcoming CSRD regulation in the European Union.
Leading the Way for Sustainable Finance
Sanofi is a pioneer of sustainable finance, with two Sustainability-linked Revolving Credit Facilities since 2020 and a Sustainability-Linked Bond, linked to its Global Health Unit, since 2021.
Environmental, Social and Governance Performance
ESG and commercial considerations are intrinsically linked and ongoing progress in our ESG performance is vital for Sanofi to succeed and grow in a sustainable way.
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
SCORE |
|
|
|
|
|
|
|
|
|
86/100 |
21.2 |
70/100 |
A |
Climate |
B |
4.3/5 |
3.47/5 |
64/100 |
|
New rating done in 2022 |
|
|
|
|
|
|
|
|
|
One of the highest scores across all sectors globally 80 points for its solid fundamentals & strong preparedness opinion of 6 points |
11th among 455 pharmaceutical companies |
Percentile of 96 within 157 scored companies in the industry |
Within the top 6 highest rated pharmaceutical companies |
Leading position |
1st decile of the 476 companies in the industry |
With very high rating across the 3 pillars ESG |
Top 10 company |
1st pharma company out of 57 |
Vs previous rating
Scores assigned by the rating agencies are not equivalent.
For most recent ESG information, see also our:
Quarterly results
ESG information throughout the quarterly results presentations and in the quarterly press releases
ESG Newsletters
Bi-annual newsletter for investors with progress updates on our CSR strategy implementation.
ESG report
Chapter 4 of the French Universal Registration Document (Declaration of Extra-financial Performance)
Transparency is important to us:
Our US Prescription Medicine Pricing Principles
We work passionately to prevent, treat and cure illness and disease, understand and solve healthcare needs of people across the world, and transform the practice of medicine.
